Recent

% | $
Quotes you view appear here for quick access.

Genomic Health Inc. Message Board

  • stupid_hobo73 stupid_hobo73 Aug 6, 2009 11:11 AM Flag

    S&P

    Reiterates BUY opinion on GHDX but lowers 12mo price target to $23 from $26 on revised price-to-sales analysis.

    3rd qtr loss was .04 more than they projected and revs were slightly lower. New full year 2009 estimate lowered by .09 to -.42 and 2010 full year estimate lowered by .12 to +.22 per share.

    S&P cited higher sales and marketing costs and a recessionary impact on tests delivered for their changes.

    They remain positive on OncoType DX's long term prospects.

 
GHDX
27.08+0.74(+2.81%)Jul 31 4:00 PMEDT